SCHEMBL760262

SCHEMBL760262

COc1cc(C(=O)C(=O)O)ccc1O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.82
KMT2A Q03164 2/20 0.82
RAB9A P51151 1/20 0.82
HTT P42858 1/20 0.73
SLC22A6 Q4U2R8 1/20 0.70
SLC22A8 Q8TCC7 1/20 0.70
HSD17B2 P37059 1/20 0.58
BLM P54132 2/20 0.57
CYP1A2 P05177 1/20 0.57
HSP90AA1 P07900 1/20 0.57
HSP90AB1 P08238 1/20 0.57
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
ALDH1A1 P00352 3/20 0.53
GAA P10253 2/20 0.53
TSHR P16473 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30921173 1.00 MEN1 (0.82) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL15289000 0.90 MEN1 (1.00) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL29532454 0.90 MEN1 (1.00) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL23829497 0.86 MEN1 (0.83) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL310113 0.85 MEN1 (0.82) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL10339186 0.85 MEN1 (0.82) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL10339187 0.85 MEN1 (0.82) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL30892512 0.85 MEN1 (0.82) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL7820973 0.85 MEN1 (0.59) MEN1KMT2ARAB9AHTTSLC22A6
SCHEMBL339242 0.85 CA12 (0.71) MEN1KMT2ARAB9AHTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217093-B1 FLAVOUR-MODULATING COMPOUNDS GIVAUDAN SA (CH) 2012-03-21 EP claimed
EP-2217093-A1 FLAVOUR-MODULATING COMPOUNDS Givaudan SA (CH) 2010-08-18 EP claimed
WO-2009055953-A1 FLAVOUR-MODULATING COMPOUNDS GIVAUDAN SA (CH) 2009-05-07 WO claimed
CN-120058496-A Preparation method and application of vanillin 浙江医药股份有限公司昌海生物分公司 2025-05-30 CN disclosed
CN-115925524-B Method for preparing vanillin from 4-methyl guaiacol 安徽圣诺贝化学科技有限公司 2024-06-25 CN disclosed
WO-2024105255-A1 METHOD FOR MANUFACTURING SYNTHETIC VANILLIN DEASYL SA (CH) 2024-05-23 WO disclosed
EP-4371971-A1 METHOD FOR MANUFACTURING SYNTHETIC VANILLIN Deasyl SA (CH) 2024-05-22 EP disclosed
CN-117630266-A Method for judging vanillin oxidation end point based on thin-layer chromatography 重庆欣欣向荣精细化工股份有限公司 2024-03-01 CN disclosed
CN-117305199-A Recombinant bacterium and application thereof in synthesis of 4-hydroxy-3-methoxybenzoic acid 杭州唯铂莱生物科技有限公司 2023-12-29 CN disclosed
CN-117304008-A Vanillin synthesis and reaction progress monitoring method 上海应用技术大学 2023-12-29 CN disclosed
US-20230022284-A1 AN ELECTROCHEMICAL METHOD FOR PREPARING VANILLIN OR ITS DERIVATIVES RHODIA OPERATIONS (FR) 2023-01-26 US disclosed
EP-2217093-B1 FLAVOUR-MODULATING COMPOUNDS GIVAUDAN SA (CH) 2012-03-21 EP disclosed
EP-2217093-A1 FLAVOUR-MODULATING COMPOUNDS Givaudan SA (CH) 2010-08-18 EP disclosed
WO-2009055953-A1 FLAVOUR-MODULATING COMPOUNDS GIVAUDAN SA (CH) 2009-05-07 WO disclosed
WO-2009055953-A1 FLAVOUR-MODULATING COMPOUNDS GIVAUDAN SA (CH) 2009-05-07 WO disclosed
WO-2002044128-A2 SALICYLATE ANALOGS AS INTERLEUKIN-4 ANTAGONISTS SUNESIS PHARMACEUTICALS, INC. (US) 2002-06-06 WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
US-4385006-A Process for preparing aromatic nitriles 501 SOCIETE FRANCAISE HOECHST (FR) 1983-05-24 US disclosed
US-4384137-A CATALYTIC OXIDATION WITH CUPRIC IONS SOCIETE FRANCAISE HOECHST (FR) 1983-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022284-A1 AN ELECTROCHEMICAL METHOD FOR PREPARING VANILLIN OR ITS DERIVATIVES VRK1, COMT, VRK2 MEN1 2728/4885KMT2A 3628/4885RAB9A 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.